# Early phase 1 carcinoma trials recruiting: 47 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 47 trials in early phase 1 for carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 carcinoma trials: 47 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 47
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07892300 | Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Lung Cancer, Mesothelioma, Suspected Lung Cancer, Suspected Mesothelioma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892300) |
| October 15, 2026 | NCT07875946 | 68Ga- and 18F-CAIX PET Imaging Study | Peking University First Hospital | Early phase 1 | Recruiting | Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875946) |
| October 13, 2026 | NCT07869823 | Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck | Vanderbilt-Ingram Cancer Center | Early phase 1 | Recruiting | Cutaneous Squamous Cell Carcinoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869823) |
| October 8, 2026 | NCT07865832 | A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma | Sponsor not shown (see the record) | Early phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865832) |
| August 28, 2026 | NCT07793500 | YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Early phase 1 | Recruiting | NSCLC, Advanced Solid Tumor | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793500) |
| August 27, 2026 | NCT07790939 | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer | Peking University Cancer Hospital & Institute | Early phase 1 | Not yet recruiting | Epithelial Ovarian Cancer, Ovarian Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790939) |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| August 3, 2026 | NCT07741565 | Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) | Vanderbilt-Ingram Cancer Center | Early phase 1 | Recruiting | HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741565) |
| July 16, 2026 | NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | Royan Institute | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709299) |
| July 8, 2026 | NCT07689643 | Safety and Preliminary Efficacy of \[177Lu\]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | Metastatic Non-small Cell Lung Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689643) |
| June 26, 2026 | NCT07671092 | Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC | RayzeBio, Inc. | Early phase 1 | Recruiting | Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671092) |
| June 18, 2026 | NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | Base Therapeutics (Shanghai) Co., Ltd. | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657416) |
| June 8, 2026 | NCT07631299 | Nebulized AER101 in Pre-op NSCLC | University of Oklahoma | Early phase 1 | Not yet recruiting | Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631299) |
| June 5, 2026 | NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | University of California, Irvine | Early phase 1 | Recruiting | Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Ductal Carcinoma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628634) |
| June 4, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | University of Arizona | Early phase 1 | Recruiting | Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627191) |
| April 28, 2026 | NCT07553767 | Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | Ningbo No.2 Hospital | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma, HEPATITIS B CHRONIC, Hepatitis B Chronic Infection | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553767) |
| March 27, 2026 | NCT07498595 | TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC | Tianjin Medical University General Hospital | Early phase 1 | Not yet recruiting | EGFR-TKI-resistant Non-Small Cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07498595) |
| March 23, 2026 | NCT07487402 | Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic... | Zhejiang University | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487402) |
| March 3, 2026 | NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | University of Texas Southwestern Medical Center | Early phase 1 | Recruiting | Resectable Hepatocellular Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446257) |
| February 27, 2026 | NCT07439120 | Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Early phase 1 | Recruiting | Urothelial Carcinoma (UC) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439120) |
| January 20, 2026 | NCT07352345 | Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Not yet recruiting | Malignant Neoplasm of Liver | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07352345) |
| December 19, 2025 | NCT07295262 | NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC | West China Hospital | Early phase 1 | Recruiting | Liver Cancer, Adult | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295262) |
| December 16, 2025 | NCT07286318 | A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286318) |
| November 24, 2025 | NCT07246304 | TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC | TCRCure Biopharma Ltd. | Early phase 1 | Recruiting | Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246304) |
| July 16, 2025 | NCT07067905 | Clinical Evaluation of \[68Ga\]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma | Chinese PLA General Hospital | Early phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma and Glioblastoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07067905) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 3 |
| Vanderbilt-Ingram Cancer Center | 3 |
| Emory University | 2 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2 |
| University of Texas Southwestern Medical Center | 2 |
| Second Affiliated Hospital of Nanchang University | 1 |
| University of California, Irvine | 1 |
| RayzeBio, Inc. | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| Radiopharm Theranostics, Ltd | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Rutgers, The State University of New Jersey | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Chinese PLA General Hospital | 1 |
| Chang Gung Memorial Hospital | 1 |
| Institut Cancerologie de l'Ouest | 1 |
| Royan Institute | 1 |
| Shanghai Changzheng Hospital | 1 |
| Ningbo No.2 Hospital | 1 |
| Tianjin Medical University General Hospital | 1 |
| BioSyngen Pte Ltd | 1 |
| Children's Hospital of Philadelphia | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Fudan University | 1 |
| Base Therapeutics (Shanghai) Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 18 |
| United States | 17 |
| Australia | 2 |
| New Zealand | 1 |
| South Africa | 1 |
| Taiwan | 1 |
| France | 1 |
| Iran | 1 |
| Spain | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Transcription services in the United States](https://specstream.ai/data/businesses/transcription-services/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Business law firms in the United States](https://specstream.ai/data/businesses/business-law-firms/united-states)
- [Cosmetic surgery practices in the United States](https://specstream.ai/data/businesses/cosmetic-surgery-practices/united-states)
- [Employment law firms in the United States](https://specstream.ai/data/businesses/employment-law-firms/united-states)
